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Abstract
Objective: The objective of this observational study was to investigate the effectiveness, safety and tolerability of
baclofen in individualised doses for the treatment of alcohol dependence in a sample of patients suffering from
additional co-occurring mental disorders.
Methods: Fifteen subjects requesting baclofen treatment to achieve abstinence from, or reduction of, alcohol
consumption, were included in the study. Baclofen was titrated individually responding to the participants' reports of
drug side effects and reductions in drinking and craving. At the start and the end of the observation period (24
weeks) patients self-reported their number of standard drinks per day and rated their alcohol craving by means of
the Obsessive Compulsive Drinking Scale (OCD-S). Liver enzymes, Carbohydrate Deficient Transferrin (CDT) and
Ethyl Glucuronide in Hair (HEtG) were measured twice.
Results: At the end of the observation period eleven patients were abstinent or low-risk drinking. Mean baclofen
dose was 116 mg/d (range 30-225 mg/d). Baclofen was well tolerated and did not interfere with pre-existing
pharmacotherapy. Three patients did not benefit from the treatment. The clinical presentation of one patient
improved although his alcohol consumption remained higher than the NIAAA recommendations. We observed
indications of baclofen misuse in one patient.
Conclusion: Baclofen treatment with individually titrated doses between 30 mg/d to 200 mg/d was associated
with suppression of, or reduction in, alcohol consumption and craving in the majority of patients. In view of the small
sample size, high motivation of the participants, and absence of a control group we caution against an
overestimation of our findings.
Keywords: Alcohol dependence; Individualised titration; GABA B
receptor agonist; Baclofen; Clinical observation
Introduction
In Switzerland, naltrexone, acamprosate and disulfiram are the only
medications licensed for the treatment of alcohol dependence but their
effect-size is rather small [1-3].
Ethanol affects various biochemical processes such as
neurotransmitter release, enzyme function, and ion channel kinetics,
but the specific molecular sites to which ethanol molecules bind are
still only beginning to be understood [4].
However, GABA mechanisms seem to be important for the
motivational effects of alcohol [5]. It was [6] postulated that pre- and
postsynaptic GABA B receptors modulate alcohol related reward and
reinforcement mechanisms. The activation of these receptors with the
GABA B receptor agonist baclofen inhibits dopaminergic neurons
indirectly and directly [7]. The importance of the GABA B receptor in
the reinforcing and motivational properties of alcohol was confirmed
[8].
Preclinical trials [9] demonstrated that baclofen in rodents reduced
alcohol consumption and increased abstinence. Further studies
[10-13] indicated the effectiveness of baclofen in maintaining
abstinence and suppressing craving.
In a double blind, randomised, placebo controlled trial the efficacy
and safety of 10 mg baclofen t.i.d. in promoting alcohol abstinence in
alcohol dependent patients was shown [14]. Moreover, the safety and
efficacy of baclofen (10 mg t.i.d.) in a randomised, double blind
controlled trial in a population of alcohol dependent patients with
liver cirrhosis was demonstrated [15]. In contrast, no evidence for the
efficacy of 10 mg baclofen t.i.d. in the treatment of alcohol dependence
was found in another study [16]. In another 12 week trial [17] the
efficacy of 30 or 60 mg/d of baclofen and placebo were compared in a
group of alcohol dependent patients. It was demonstrated that even at
higher doses baclofen was safe and even more effective in maintaining
abstinence and suppressing craving. The safety of higher doses of
baclofen (80 mg) in combination with alcohol intoxication was shown
[18] in a trial with heavy social drinkers. Two case reports [19,20]
showed a total and prolonged suppression of symptoms of alcohol
dependence with higher doses of baclofen without severe side effects.
An account of four cases treated with baclofen of up to a maximum
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dose of 125 mg/d either alone, or in combination with acamprosate or
naltrexone, was published [21]. In two cases they found prolonged
abstinence even after the dosage was reduced to 50 mg/d. Recently, in
a sample of 132 participants the safety and efficacy of higher doses of
baclofen in maintaining abstinence or lower risk drinking over a
period of 12 months was confirmed [22]. Abstinence or reduced
consumption in eight of twenty-one patients with psychiatric
comorbidities was described in a selected case series [23]. In
Switzerland, baclofen as an off-license treatment option for alcohol
dependence has received broad publicity, following the German
publication of Oliver Ameisen’s self-reported cure from severe
alcoholism [24].
However, given the partially controversial findings of the hitherto
existing studies and the unresolved questions like optimal dosing and
potential usefulness in alcohol dependent patients with co-occurring
disorders, the aim of our observation was to investigate feasibility,
safety and tolerability of individualised doses of baclofen in a sample
of alcohol dependent patients with co-occurring mental disorders
while retaining the pre-established medication for co-occurring
conditions. Moreover, our approach differed from former protocols by
including biological markers of alcohol use as an objective outcome
measure rather than only relying on self-reported data.
Methods
Fifteen out-patients participated in the observational study because
of their craving for, or consumption of, alcohol. Fourteen out of these
fifteen had undergone detoxification treatment in the past and had
prior pharmacotherapy for their alcohol dependence without success.
All persons asking for the treatment, independent of their aim,
(abstinence or reduction in alcohol consumption) were included.
Criteria for exclusion were pregnancy, a history of seizure or a
psychotic disorder. Consecutively, participants commenced treatment
having been informed about the procedure, possible side effects and
the off-license nature of the medication. They all signed informed
consent.
The ethics commission of the Canton Zürich, Switzerland agreed
with the study-procedure.
Before starting treatment (T0) blood samples were taken to
determine Mean Cell Volume (MCV), Alanine Aminotransferase
(ALAT), Aspartate Aminotransferase (ASAT), Gamma-glutamyl-
transpeptidase (GGT) and Carbohydrate Deficient Transferrin (CDT).
At this time (T0) we also collected the score of the Obsessive
Compulsive Drinking Scale (OCD-S; [25]) and the number of
standard drinks/d. The results of the OCD-S were discussed with each
participant. All participants attended their weekly Treatment As Usual
(TAU) where the individual craving and drinking was discussed. The
preexisting pharmacotherapy was continued without significant
changes over the course of the observation. Only one woman
temporarily reduced her benzodiazepine dosage for two weeks. No
patient participated in any other treatment program for alcohol-
dependence during our study.
Initially the prescribed baclofen dosage was 5 mg t.i.d. and then,
after possible side effects (particularly excessive sleepiness) had
disappeared, the evening dose was increased to 10 mg. In a further
stage, first the midday dose and finally the morning dose, was
increased. We followed this procedure for each increase in dose. Using
this practice we tried to minimise possible side effects. The final
dosage was found by considering possible side effects and maximal
craving suppression as reported by the participants.
After 24 weeks MCV, ALAT, ASAT, GGT, number of standard
drinks/d and the score of the OCD-S were determined again (T2).
Ethyl Glucuronide (HEtG), a metabolite of alcohol detectable in hair
[26] was analysed by obtaining hair samples cut as close to the scalp as
possible at T2. The proximal 3 cm of hair corresponded to the last 3
months of baclofen treatment assuming a hair growth of 1 cm/month.
Whenever possible we also detected HEtG in the hair 3 cm to 6 cm
distal from the scalp (T1) covering the first three months of the study.
In eleven cases out of fifteen the whole time window of the medication
was monitored by hair testing. HEtG in the head hair samples was
determined quantitatively with gas chromatography–negative
chemical ionisation–tandem mass spectrometry [27]. HEtG values
between 7 and 40 pg/ml (considering the cut-off value 30 pg/mg with a
measurement uncertainty of ± 25%) correspond with moderate
alcohol consumption [28,29].
According to proposed cut-off values [28,29], HEtG values between
7 pg/ml and 40 pg/ml (under consideration of the cut-off value of 30
pg/mg with the measurement uncertainty of ± 25%) correspond with
moderate alcohol consumption.
Data analysis was done with IBM SPSS Statistics (version 20.0; IBM
Corp., Sumers, NY). Intra-individual differences between T0 and T2
were tested using the Wilcoxon signed-rank test. Two-tailed
significance-level was set at 0.05. Due to multiple comparisons,
significance-level was adjusted using Bonferroni correction from 0.05
to 0.05/8=0.00625. Differences in HEtG-values are reported without
statistical testing, because this variable was not continuous.
Results and Cases
Preliminarily we describe the cases of an abstinent woman suffering
from her craving and of a man who did not benefit from treatment.
Case 4
A 44-year old woman on a disability pension and a 10 years' history
of alcohol dependence attended our outpatient clinic. Over the past
ten years she had consumed approximately 16 standard drinks/d and
undergone five withdrawal treatments on an inpatient basis. She had
been maintained on methadone for the last 15 years because of her
heroin dependence and also suffered from a borderline-personality
disorder, recurring episodes of depression, an Attention Deficit
Hyperactivity Disorder (ADHD), and a Post Traumatic Stress
Disorder (PTSD).
After her last withdrawal treatment she requested baclofen
medication because of her severe craving. In the past she was
prescribed acamprosate and disulfiram, but these drugs had been
unsuccessful. We initiated treatment at a dose of 5 mg baclofen t.i.d.
When reaching a dosage of 120 mg/d her craving was totally
suppressed. Side effects described by her were weakness and tiredness
at the beginning of the treatment and whenever the dosage was
increased. These side effects disappeared within three days after stable
dosing. All of her blood values, including CDT, were within the
normal range.
HEtG was not detectable throughout the observation period.
Twenty weeks after the start of the observation baclofen was reduced
to 100 mg/d. At T2 there had been no changes in her blood values, but
the OCD-S had fallen from 33 at baseline to 8.
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Case 7
A 42 year old, unemployed, single man had a history of
approximately 8 years of severe drinking (about 20 standard drinks/d).
He also suffered from an adult ADHD, a mixed personality disorder
with narcissistic, dissocial and emotionally unstable features and
recurrent depressive episodes. He smoked cannabis and occasionally
consumed cocaine. He had also used Gamma-hydroxybutyrate (GHB)
in the past. Inpatient withdrawal treatments had been ineffective in
achieving prolonged periods of abstinence and disulfiram-medication
had been similarly unsuccessful. When the trial was initiated his
depressive disorder was in remission.
At baseline ASAT, ALAT, GGT were slightly raised, CDT was
elevated (Table 1) and the OCD-S was 15. Treatment was started with
5 mg baclofen t.id. During the next meeting he compared the effects of
baclofen to those of GHB. Gradually we increased the dosage to 150
mg/d. The patient described a reduction in craving, but was not totally
satisfied with the effect. Without consulting his physician, he increased
the dosage form 150 mg/d to 200 mg/d over three days. However,
tiredness and dizziness were the only side effects he described.
Moreover, he reported that his craving was minimised. Although the
patient reported a reduction of his craving and drinking, we measured
a CDT value of 7.6% at the end of the investigation. ASAT, ALAT and
GGT values also remained elevated. HEtG was raised to 320 pg/mg
during the last three months of the trial.
When shown these results, the patient disclosed that his alcohol
consumption had been unaffected by baclofen, but stated that he felt
more relaxed and more self-confident when taking the medication.
Although his alcohol consumption had increased he requested
continuation of the treatment but agreed to a dosage reduction to 150
mg/d. We cannot exclude the possibility that he found other sources to
purchase baclofen.
All participants, ten Caucasian men and five women, median age 40
years, range 32 to 60 years, completed the observation. Two women
were abstinent when the observation started and no withdrawal
management was necessary in any participants. The duration of
alcohol dependence ranged from 2 to 28 years with a median duration
of 10 years. One male participant did not suffer from co-occurring
mental disorders. Three participants (one female and two males)
occasionally took disulfiram or clomethiazol.
At the end of the observation the individual baclofen dosages
ranged between 30 mg and 225 mg/d. Mean baclofen dose was 116
mg/d, while median dosage was 100 mg/d. Ten participants used doses
between 75 mg/d and 125 mg/d, three men had dosages between 200
mg/d and 225 mg/d, one woman used 30 mg/d and an additional 10
mg in risky situations. One woman was treated with a dosage of 60
mg/d.
The following, temporary Adverse Effects (AEs) were experienced
(frequency in parentheses): tiredness, drowsiness or sedation (14),
dizziness (4), headache (3), nausea (3), muscle weakness (1), visual
disturbances (1), back pain (1) and erectile dysfunction (1). No
individual withdrew from the observation because of AEs. These AEs
appeared to be in response to increases in dose and would resolve
within three to five days. One person experienced no side effects. A
potential Serious Adverse Event (SAE) was observed in one participant
where there were indications of misuse (see Case 7 and Discussion).
According to ICD-10 diagnostic criteria co-occurring mental health
disorders (incidence in parentheses) were: depressive episodes (12),
cocaine dependence or misuse (7), opioid dependence (4), personality
disorders (4), attention deficit hyperactivity disorders (4), anxiety
disorders (2), post-traumatic stress disorders (1) and eating disorders
(1). Fourteen patients suffered from concomitant mental disorders and
five patients were diagnosed with four or more mental disorders. One
man had no co-occurring mental disorder. Medications prescribed
along with baclofen (incidence in parentheses) were: antidepressants
(14), benzodiazepines (7), methadone or buprenorphine (4),
methylphenidate (4), mood stabilisers (2) and antipsychotics (2).
At the end of the observation we found no statistically significant
reductions in CDT, MCV, ASAT, ALAT and GGT in 13 patients
(Table 1 and Table 2).
Patient No. Gender Age [y] MCV [fl] ASAT [U/l] ALAT [U/l] GGT [U/l] CDT [%] Baclofen [mg/d]
T0 T2 T0 T2 T0 T2 T0 T2 T0 T2
1 m 35 94.0 92.0 11.0 17.0 12.0 11.0 81.0 11.0 1.8 1.5 105.00
2 f 58 94.0 90.0 17.0 18.0 18.0 22.0 46.0 6.0 2.5 1.6 75.00
3 f 34 - - 17.0 21.0 21.0 19.0 17.0 17.0 1.8 1.7 75.00
4 f 44 88.0 84.0 15.0 16.0 20.0 17.0 24.0 27.0 1.5 1.7 100.00
5 f 66 86.0 84.0 57.0 16.0 - 18.0 - 18.0 - 1.8 30.00
6 m 50 - 92.0 71.0 19.0 98.0 18.0 109.0 22.0 - 2.4 125.00
7 m 42 95.0 95.0 27.0 36.0 36.0 36.0 67.0 51.0 4.7 7.6 200.00
8 m 40 89.0 90.0 25.0 29.0 21.0 26.0 60.0 53.0 - 2.8 125.00
9 m 38 102.0 103.0 21.0 30.0 44.0 49.0 185.0 274.0 2.1 1.7 200.00
10 m 46 - - 19.0 23.0 29.0 64.0 18.0 50.0 1.7 2.1 125.00
11 f 46 99.0 96.0 27.0 33.0 24.0 28.0 23.0 11.0 9.4 2.7 60.00
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12 m 32 91.0 91.0 32.0 37.0 78.0 58.0 72.0 73.0 1.8 1.5 85.00
13 m 38 100.0 94.0 29.0 26.0 47.0 45.0 160.0 111.0 - 2.2 100.00
14 m 30 99.0 91.0 16.0 33.0 17.0 18.0 - 16.0 1.8 - 75.00
15 m 38 - - 92.0 65.0 56.0 52.0 370.0 76.0 2.2 1.8 225.00
M - 42.40 94.27 91.83* 31.73 27.93 37.21 32.06 94.76 54.40 2.84 2.36 115.66
SD - 6.66 5.33 5.11 23.26 12.64 25.31 17.21 98.11 67.81 2.34 1.56 55.19
Table 1: Blood testing results. T0: beginning of the observation; T2: end of the observation; -: missing value; *p<0.01
A statistically significant decrease was detected in mean OCD-S
total score from T0 (20.15; SD=7.28) to T2 (8.07; SD=4.87; Wilcoxon
Z=-3.06; p=0.002), and self-reported standard drinks/d (from 12.91 ±
6.46 to 2.84 ± 6.99, Wilcoxon: Z=- 2.83; p=0.005) (Table 2).
Patient No. OCD-S St. dr./d HEtG [pg/mg] Baclofen
dosage [mg/d]
Duration of
dependence [y]
T0 T2 T0 T2 T1 T2
1 26 1 14.50 1.00 11 9 105.00 7.00
2 10 2 9.50 0.10 <7 <7 75.00 16.00
3 20 8 5.00 1.50 - - 75.00 10.00
4 33 8 16.10 0 0 0 100.00 10.00
5 15 9 5.10 0 8 <7 30.00 2.00
6 27 10 19.10 1.50 - 46 125.00 2.00
7 15 - 19.70 26.00 - 320 200.00 8.00
8 20 13 16.00 2.50 8 17 125.00 7.00
9 30 - - - 23 62 200.00 15.00
10 20 8 0 1.00 - 18 125.00 27.00
11 30 18 15.80 0.50 8 9 60.00 28.00
12 19 4 16.00 1.00 <7 <7 85.00 2.00
13 14 14 10.00 - 70 180 100.00 13.00
14 9 5 10.00 0.70 19 22 75.00 14.00
15 19 5 21.10 1.20 34 28 225.00 15.00
M 20.15 8.07* 12.91 2.84* - - 115.66 11.73
SD 7.28 4.87 6.46 6.99 - - 55.19 7.98
Table 2: OCD-S, standard drink/d, HEtG, baclofen dosage and duration of dependence in years. T0: beginning of the observation; T1: after 12
weeks; T2: end of the observation; -: missing value; *p<0.01
The individual results are shown in Tables 1 and 2.
In conclusion, four patients (three women and one man) achieved
abstinence and six reduced their consumption to a low or moderate
level. One female participant (case 3) described a reduction in craving.
Unfortunately she had bleached her hair so HEtG was not quantifiable
although her clinical presentation supported her statement. Patient six
stated that he was able to reduce his alcohol consumption although the
HEtG value of 46 pg/mg remained elevated.
Three male participants did not benefit from the treatment.
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Discussion
The heterogeneity of the sample was not only due to differing co-
occurring mental disorders but also differing starting conditions,
duration of dependence and differing ambitions of the participants.
The majority of the participants intended to reduce their drinking to a
non-problematic level. Fourteen of fifteen participants in our
observation had co-occurring mental disorders and were prescribed
concomitant psychotropic medication. Baclofen seemed not to
interfere with the other psychotropic drugs and was well tolerated by
all participants. Transient side effects had no influence on treatment
adherence. Over the course of the observation no participant dropped
out. The individualised titration of baclofen following the needs,
requests and mental states of each participant might have contributed
to these findings.
In total we saw an improvement of 12 participants. Two women
were abstinent when the observation began and remained abstinent.
Two persons, who were dependently drinking at T0 also achieved
abstinence. Six participants reduced their alcohol consumption. Their
self-declared consumption at the end of the observation of less than
2.5 standard drinks/d corresponded with the maximum HEtG value of
28 pg/mg. Two of these six patients achieved HEtG values below 10
pg/mg. Their consumption was compatible with low risk drinking
according to the recommendations of NIAAA [30]. The self-reported
reduction in alcohol consumption in those patients who were
compliant with treatment was consistent with their HEtG-levels. The
statements of drinking and craving of cases three and six could not be
confirmed by their HEtG values even though their clinical
presentation improved.
Alcohol consumption of three males increased under high and the
highest dosages of baclofen, according to their HEtG levels. However,
adherence to treatment of these men was presumably poor. During the
observation all three reported a reduction in the number of standard
drinks/d. When shown the results of their HEtG levels they disclosed
that their declarations had been inaccurate. Two of these individuals
agreed to a gradual tapering and discontinuation of baclofen which
occurred over several weeks. No additional medication was necessary
and no harm was reported during this period. Only case 7 requested
continuation of baclofen because he thought he had benefited from the
treatment by an increased self-confidence and a more relaxed
demeanour. Our experience with this case over the course of the
observation has led us to conclude that baclofen has a potential of
misuse. Therefore we advise caution in cases with poor therapy
adherence, high dosage of baclofen and a repeated request for dosage
increase.
Measures to optimise treatment adherence would be a useful
strategy for clinicians in cases where there might be a potential for
misuse to prevent overdosing (accidental or non-accidental) along
with daily administration of medication.
In total, craving reduction or suppression was achieved with a
maximum baclofen dosage of 100 mg/d for all five women and with a
maximum of 225 mg/d for seven men. This may suggest that women
experience reduced cravings with a lower dose when compared to
men.
The age of participants and the duration of dependence did not
influence the efficacy of treatment. Mean baclofen dose was 116 mg/d.
This clinical observation study is limited by the small sample size
and its design as a clinical observation. In our small observation
females improved more than males at lower dosages. Further studies
are necessary to corroborate this finding. Thirteen participants asked
for continuation of treatment, after the 24 week observation period.
Eight months after the end of the observation, ten of the participants
were stable in abstinence or low risk drinking.
The self-declared number of standard drinks/d before the
observation could not be confirmed by HEtG values. This is a second
limitation, because it is possible that participants consumed initially
more or less alcohol than their declared amount. However, at T1 ten
participants’ HEtG results were below 40 pg/mg and these results
remained stable or even decreased till T2. This may indicate the
prolonged effect of the treatment.
Absence of any blood-levels of baclofen is a third limitation and we
have been unable to find a correlation between the prescribed dosages
and the reduction or suppression of craving for, and drinking of,
alcohol in our sample. Recently, a study showed a proportional
relationship between baclofen dose and exposure but also observed
that similar doses did not lead to similar exposure [31]. Because of the
wide inter-individual variability further studies are necessary to
elucidate the association of clinical efficacy and baclofen exposure.
The effect of baclofen in suppressing dependent alcohol
consumption is questionable in the two females who were abstinent at
the beginning of our observation. However, both reported a
suppressed craving while on baclofen and remain abstinent.
The outcome of our observation might have been confounded by
three participants occasionally taking disulfiram or clomethiazol
medication. These medications were not taken regularly by any of
these participants but we cannot exclude this intake influencing the
results.
Moreover, when interpreting our findings, it should be born in
mind that the patients involved in this observation study had
specifically requested baclofen treatment as they had been convinced
of baclofen’s effectiveness. Beliefs of participants may have an
important impact on the outcome of a trial [32]. Nevertheless the
results of our study are comparable to previous findings in which
patients were not reported to be specifically biased in favour of
baclofen.
Conclusion
In our heterogeneous sample also treated with other psychotropic
medications the majority of participants benefited from the individual
titration of baclofen . In three participants we noticed a decline in their
condition. Baclofen might have a risk of misuse.
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